Breakthrough Treatments Found to Prevent Deadly HTLV-1 Infection

Melbourne,Australia – Groundbreaking research has identified the world’s first effective treatments to prevent and combat the Human T-lymphotropic virus⁤ type 1 (HTLV-1),a neglected ⁣disease that⁢ disproportionately affects Indigenous communities in Central Australia. The findings, published in the⁤ prestigious journal Cell, offer notable hope for preventing transmission and managing the debilitating diseases ‍caused by HTLV-1.

Advocacy for a Neglected Disease

For over a decade, a dedicated physician in Central‍ Australia has championed the cause of HTLV-1, working tirelessly to bring this often-overlooked virus to the ‍forefront of public health awareness. This commitment has been instrumental in driving the research and advocacy that⁢ led to these pivotal discoveries.

Research spearheaded by Professor Damian Purcell,Head of Molecular Virology at the Doherty Institute⁤ and co-lead author of the study,successfully isolated the⁣ virus from First nations donors. crucially, the ⁢study identified significant genetic⁣ differences in the HTLV-1c strains ‍prevalent in ⁣Central australia compared to the internationally common HTLV-1a strains.The new findings demonstrate that both HTLV-1 strains can cause disease in ‍mice. Notably, the HTLV-1c strain exhibited more aggressive disease characteristics. Tho, the identified drug therapies proved equally effective against both strains, marking a significant advancement in ⁣treatment⁣ potential.

Professor Purcell,‍ alongside Associate Professor lloyd Einsiedel, collaborated ⁢extensively with the National Aboriginal Community Controlled Health Organisation ⁢(NACCHO) HTLV-1 committee and the australian Department of Health. Their sustained advocacy efforts over many years culminated in ⁤the World Health Organization (WHO) formally classifying HTLV-1 as a Threatening Pathogen to Humans in 2021.

This classification has paved the way for the development of crucial WHO policies aimed at reducing international transmission and the⁣ creation of specific clinical management⁢ guidelines for HTLV-1c in Central⁤ australia, under the leadership of NACCHO.

“Despite ⁤Australia’s high burden of HTLV-1, the virus and its ⁤associated diseases are still not notifiable in most states, and true infection rates in the nation remain unknown,” stated Professor Purcell. “People at⁢ risk from HTLV-1 deserve biomedical ⁣tools similar to ‍those that provide game-changing therapeutic and prevention options for other blood-borne persistent viral infections, such as ⁣HIV.”

he added,”There is a real possibility to prevent ‍the‍ transmission of HTLV-1 and end the diseases caused by these infections. Our research findings are a major leap forward in this.”

The research team is currently engaged in discussions with the pharmaceutical companies behind the ⁢HIV antivirals utilized in this study. The goal is to explore the possibility of including HTLV-1 patients in ongoing clinical trials.⁢ Success in this endeavor would be a critical step towards ⁤these drugs becoming the first approved pre-exposure prophylaxis (PrEP) options for preventing HTLV-1 acquisition.

These vital findings received support from The Australian Center for⁣ HIV and Hepatitis Virology Research, The Phyllis Connor Memorial Trust, Drakensberg Trust, and the National⁢ Health and Medical‍ Research Council (NHMRC).

The study, titled “Combination⁢ antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1⁢ infection⁣ in vivo,” ⁣is published in⁣ the latest ⁤issue of Cell (DOI: 10.1016/j.cell.2025.06.023).

**

Public Release.‍ This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length.Mirage.News does not take institutional positions or sides, ⁣and all views, positions, and conclusions expressed herein are ⁣solely those of the author(s). View in full hear.*